Compliance becomes a selling point for pet supplements, treats

For pet supplement and treat companies, compliance is increasingly being framed as a growth strategy, not just a regulatory obligation. In an April 16, 2026, PetfoodIndustry article, Asa Waldstein, principal of Apex Compliance, said brands that build compliance into product development early, from ingredient review and supplier vetting to manufacturing oversight and marketing claim review, are better positioned to scale, win retail placement, and attract investors. He pointed to GMP-style systems, stronger internal review processes, and third-party programs such as the National Animal Supplement Council’s Quality Seal as practical ways companies can stand out as scrutiny rises. (petfoodindustry.com)

Why it matters: For veterinary professionals, this signals a pet supplement and treat market that may become more disciplined around quality, labeling, and claims, areas that directly affect clinic recommendations and pet parent trust. FDA says pet food and animal food products must be safe, truthfully labeled, and produced under sanitary conditions, while both FDA and AAFCO make clear that disease-treatment claims can push a product into drug territory. That matters in a category where marketing often outpaces evidence, and where FDA warning letters have recently targeted animal products for unsafe manufacturing practices and unapproved drug claims, including claims made online. (fda.gov)

What to watch: Expect more attention to online claims, state-by-state label compliance, and whether voluntary programs like NASC’s newly expanded treat framework gain traction as a trust signal with veterinarians, retailers, and pet parents. (nasc.cc)